Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDOPAM
2024-518139-12-00Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of Tedopi in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by GERCOR. Primary endpoint: Overall survival rate at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
Tedopi
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-518139-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518139-12-00.